North America In Vitro Diagnostics Market

North America In Vitro Diagnostics Market Analysis

North America in vitro diagnostics market, valued at USD 42 billion in 2024, is estimated to reach USD 44 billion in 2025 and USD 75 billion by 2035, representing a CAGR of 5.5% during the forecast period.

To learn more about this report, request a free sample copy

The new market research study report covers an in-depth analysis of industry trends, market size, patent analysis, competitive landscape, emerging trends, and future forecast.

The COVID-19 outbreak and the rising prevalence of chronic diseases in the United States have sparked the demand for in vitro diagnostics kits and reagents for accurate and faster diagnosis. In vitro diagnostics refers to the innovative technologies, reagents, and services that are utilized for diagnosing a broad range of diseases. These tests are conducted on human samples such as blood or tissues within glass tubes for diagnosing diseases, monitoring treatment progress and analyzing healthcare outcomes. According to the Centers for Disease Control and Prevention, one in three Americans is at greater risk of diabetes in the United States. It is worth highlighting here that asthma, arthritis, cardiovascular diseases, cancer, chronic kidney diseases, diabetes, and depression are some of the highest recorded diseases in the United States. It is worth mentioning here that the majority of healthcare decisions are made on the basis of laboratory test results, showcasing the importance of in vitro diagnostics tools for patient care.

These cutting-edge in vitro diagnostics tools significantly assist in disease diagnosis, progression, and tracking of treatment outcomes. Owing to the ongoing trend of advanced in vitro diagnosis tools, instruments, kits, and reagents, the established players in this industry are prioritizing their R&D efforts to facilitate the development of home-based in vitro diagnostics kits that aid in disease monitoring and diagnosing remotely. The home-based in vitro diagnostics kits offer several advantages such as convenience, efficiency, and self-dependency - they significantly reduce the burden on healthcare experts to track patient health.

Furthermore, the primary focus of key industrial leaders will be on next generation sequencing technology that enables early detection of disease indications to improve patient outcomes. For instance, in May 2023, a start-up Aptitude Medical, aimed to develop a suite of innovative molecular diagnostic assays that can be utilized at home and for point-of-care. The startup company has received USD 53.7 million of capital investment from the US Department of Health's Biomedical Advanced Research and Development Authority. The funding contract with BARDA covers USD 19.6 million in base funding and USD 34.1 million for the development of at-home molecular tests for COVID-19 and other multiplex tests for diagnosing infectious diseases. Given the significance offered by the in vitro diagnostics tools and ongoing efforts for the development of advanced diagnosis solutions, the North America in vitro diagnostics market is anticipated to grow at a higher pace during the forecast period.

North America In Vitro Diagnostics Market Segmentation Insights

This regional market research report covers the detailed analysis of future growth and emerging investment trends across various segments mentioned below:

North America In Vitro Diagnostics Market: Report Attributes / Market Segmentations

One of the critical objectives of studying the North America in vitro diagnostics market report is to provide detailed analysis on existing market size, emerging trends, competitive landscape, growth scenarios and collaborations between key players active in this field. Our year-wise analysis of various segments of the industry provides in-depth information about rising trends and future investment opportunities for industrial stakeholders in the next decade. Further, our market report also covers key trends and future forecasts across various segments such as type of products, test types, therapeutic areas, and end users. In order to add strength to our study, we have provided three market models, namely the base model, conservative model, and optimistic model, representing growth opportunities within the North America IVD market.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD unless otherwise specified. The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry.

North America In Vitro Diagnostics Market Share Insights

Market Share by Type of Products

Based on type of products, the North America in vitro diagnostics market is distributed into reagents, instruments and services. According to our projection, reagents account for the largest share in 2024, and the trend is likely to continue during the forecast period. The growth of reagents can be attributed to the growing usage of chemical reagents for disease diagnosis in large quantities. Driven by the high demand, the reagents are replenished quickly in the laboratories, which is anticipated to drive maximum revenues for the industrial leaders engaged in the market.

Market Share by Point of Testing

North America IVD market is distributed into laboratory testing and point-of-care testing on the basis of place where the tests are conducted. According to our projection, laboratory testing accounts for the highest market share in 2024, and the trend is likely to remain unchanged during the forecast period. The growth in this field can be attributed to the growing requirement for high throughput in vitro disease diagnostic techniques.

Market Share by Technology

Based on the type of technology, the North America in vitro diagnostics market is segmented into clinical chemistry, hematology, immunoassay, molecular diagnostics, and others. Currently, immunoassays are likely to hold the maximum share of the market in 2024. According to our projection, clinical chemistry will grow at a steady rate during the forecast period.

Market Share by End Users

North America in vitro diagnostics industry has been distributed across hospitals, laboratories and others based on the type of end users. Presently, hospitals are likely to hold the largest share of this market in 2024, and the trend is likely to remain unchanged during the forecast period. According to the Centers for Medicare & Medicaid Services, there are nearly 320,000 CLIA certified laboratories in the US. Driven by the growing number of such labs for disease diagnosis, the laboratory segment is likely to grow at a substantial rate during the forecast period.

North America In Vitro Diagnostics Market Dynamics

North America In Vitro Diagnostics Market (Distribution by Products (Instruments, Reagents, and Other Products), by Technology (Immunoassay, Hematology, Clinical Chemistry, Molecular Diagnostics, Coagulation Microbiology, and Other Technologies), by Application (Infectious Disease, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune Disease, Drug Testing, and Other Applications), by End User (Hospitals, Laboratories, and Other End Users) and Key North American Countries (US and Canada): Industrial Trends and Regional Forecast, 2024-2035; the market study report provide a comprehensive analysis on the market growth, current size, emerging trends, potential competitors, investment opportunities and future growth. Additionally, the research report features an in-depth analysis of the increasing research and development efforts of key stakeholders active in this domain for future growth and innovation. Key takeaways of this regional market report are discussed below.

Growth Drivers: Rising Incidence of Chronic Diseases, Favorable Reimbursement, and Demand for Point of Care Testing

Key drivers that are propelling the North America in vitro diagnostics market include growing incidence of chronic diseases and rising demand for point of care diagnostics. According to the Centers for Disease Control and Prevention report, nearly 129 million people in the United States are suffering from one or more chronic diseases. Further, the report of the American Diabetes Association states that around 1.2 million Americans are diagnosed with diabetes annually. The growing incidence of chronic disease in the United States has underscored the requirement for rapid in vitro diagnostic kits and instruments that ensure quick results. In this context, owing to the convenience offered and the potential to generate quick results, point-of-care testing is gaining popularity in the United States. As the technology continues to evolve in point-of-care testing (POCT) devices and the rising use of telemedicine, these POCT devices will be utilized for diagnosing a broad range of diseases and enable remote patient monitoring. Additionally, the favorable reimbursement and government support further will be a major growth driver during the forecast period.

Market Challenges: High Adoption Risk, Competitive Landscape, and High Cost of Diagnostic Instruments

Despite technological advancements and a dynamic ecosystem for the adoption of in vitro diagnostics in the healthcare sector, the market still faces challenges that hamper the overall progress of the industry. One of the significant restraints is slow adoption as IVD technologies require extensive validation and have to surpass the regulatory guidelines for a successful launch into the market. Additionally, the development and introduction of IVD tests and technologies is a costly approach. It requires significant investment in research and development, which can be difficult for smaller companies and even established players. Additionally, the IVD industry in North America is highly competitive, featuring several industrial leaders. In a competitive scenario, developing unique in vitro diagnostic tests, kits, and reagents at competitive costs may create challenges for the key players in this industry.

Market Trends: Integration of Artificial Intelligence throughout IVD Labs and Shift towards Next Generation Sequencing for Tailored Treatment

North America in vitro diagnostics market is witnessing continuous evolution to develop advanced IVD testing instruments, platforms and reagents to enhance patient outcomes. Currently, the stakeholders active in this field are focusing on future technologies such as integration of artificial intelligence and in vitro diagnostics. Implementation of artificial intelligence in IVD labs becomes crucial for easy handling and real-time diagnosis of diseases. Further, AI technology significantly helps to reduce pre- and post-analytical process time. AI integration represents compelling opportunities in countries like the US, as it offers high work efficiency, reduced labor costs, and enhanced productivity. Additionally, the growing shift towards next-generation sequencing and immunoassays for disease diagnosing at the molecular level has offered lucrative opportunities to drive innovations in this field. For instance, in 2023, Beckman Coulter and Fujirebio signed a collaboration agreement to extend their research of targeted analytes such as pTau217 plasma assay and a Beta Amyloid 1-42 plasma assay. These advanced assays have been developed to be utilized on the recently launched Beckman Coulter Dxl 9000 Immunoassay analyzer to perform clinical assays. Driven by the ongoing trends and emergence of precision medicine, the North America IVD market is estimated to grow at a substantial rate during the forecast period.

Leading Companies Engaged in North America In Vitro Diagnosis Market

Examples of key players in North America in vitro diagnostics industry (also profiled in this report; the complete list of companies is available in the full report) include Abbott Laboratories, Agilent Technologies, BD, Bio-Rad, Danaher, Exact Sciences, Hologic, Illumina, LabCorp, Qiagen, Quest Diagnostics, QuidelOrtho and Thermo Fisher Scientific. This regional IVD market report includes an easily searchable excel database of the leading companies that offer vitro diagnostic solutions in North America.

Recent Developments in North America In Vitro Diagnostics Market

Some of the recent developments in the Vitro Diagnostics market in North America are mentioned below.

• In May 2026, Roche agreed to acquire US-based PathAI for $750 million upfront, with up to $300 million in milestone payments, strengthening its diagnostics division’s AI-enabled pathology capabilities. The deal built on an existing partnership and aimed to scale digital diagnostics tools across North America, improving cancer diagnosis workflows and precision medicine applications.
• In April 2026, QuidelOrtho completed its $100 million acquisition of LEX Diagnostics, expanding its point-of-care molecular diagnostics portfolio. The acquired LEX VELO system, which had received FDA 510(k) clearance and a CLIA waiver in February 2026, enabled rapid PCR testing for respiratory infections, supporting commercialization and faster diagnostics adoption across US healthcare settings.
• In April 2026, ViroGates submitted a De Novo application to the US FDA for its suPARnostic TurbiLatex test, a novel in vitro diagnostic measuring chronic inflammation. The filing represented a key regulatory milestone toward US market entry, following FDA confirmation of the De Novo pathway in 2025 for this first-of-its-kind diagnostic product.
• In April 2026, CareDx agreed to divest its lab products business, including IVD PCR and NGS diagnostic kits, to EuroBio Scientific for $170 million. The transaction allowed CareDx to focus on US-based precision medicine testing services and digital solutions, streamlining operations and reallocating capital toward higher-growth diagnostics services in North America.
• In March 2026, Illumina and Labcorp expanded their collaboration to develop next-generation sequencing-based in vitro diagnostic tests, focusing on oncology biomarkers and whole-genome sequencing. The partnership aimed to improve access to precision diagnostics in North America, generate clinical evidence for payer coverage, and accelerate the development of advanced genomic testing solutions.
• In January 2026, Prenosis secured a $20 million BARDA contract alongside a $20 million Series A financing round to advance its AI-driven diagnostic and therapeutic platform. The funding was intended to support clinical validation, regulatory advancement, and commercialization of diagnostics for critical care conditions, reinforcing US government backing for next-generation in vitro diagnostic technologies.